Orbimed Advisors - MEREO BIOPHARMA GROUP PLC ownership

MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 64 filers reported holding MEREO BIOPHARMA GROUP PLC in Q3 2022. The put-call ratio across all filers is 1.76 and the average weighting 0.0%.

Quarter-by-quarter ownership
Orbimed Advisors ownership history of MEREO BIOPHARMA GROUP PLC
ValueSharesWeighting
Q1 2023$5,476,984
-31.1%
7,747,891
-26.9%
0.11%
-28.9%
Q4 2022$7,954,142
-12.9%
10,605,5220.0%0.15%
-10.6%
Q3 2022$9,132,000
-16.0%
10,605,522
+9.2%
0.17%
-13.7%
Q2 2022$10,877,000
-43.7%
9,711,422
-43.8%
0.20%
-37.1%
Q1 2022$19,336,000
-30.0%
17,264,7640.0%0.31%
-11.8%
Q4 2021$27,624,000
-33.9%
17,264,7640.0%0.36%
-22.7%
Q3 2021$41,781,000
-23.7%
17,264,7640.0%0.46%
-17.1%
Q2 2021$54,730,000
-5.9%
17,264,764
+0.0%
0.55%
+1.8%
Q1 2021$58,183,000
+17.6%
17,264,763
+25.0%
0.54%
+25.6%
Q4 2020$49,463,00013,816,4880.43%
Other shareholders
MEREO BIOPHARMA GROUP PLC shareholders Q3 2022
NameSharesValueWeighting ↓
COMMODORE CAPITAL LP 1,972,958$4,775,0001.26%
Altium Capital Management LP 1,250,000$3,025,0000.79%
Rubric Capital Management LP 11,300,000$27,346,0000.76%
Vivo Capital, LLC 6,907,189$16,715,0000.75%
DAFNA Capital Management LLC 1,126,613$2,726,0000.72%
SILVERARC CAPITAL MANAGEMENT, LLC 365,661$885,0000.50%
Orbimed Advisors 17,264,764$41,781,0000.46%
Delphi Management Partners VIII, L.L.C. 256,734$621,0000.45%
Endurant Capital Management LP 746,514$1,807,0000.41%
Affinity Asset Advisors, LLC 650,000$1,573,0000.40%
View complete list of MEREO BIOPHARMA GROUP PLC shareholders